Abstract
INTRODUCTION

38
The introduction of cefepime into clinical practice was widely accepted due to its broad spectrum 39 activity. Cefepime is active against such organisms as Acinetobacter baumannii, Pseudomonas 40 aeruginosa and Enterobacteriaceae with relatively low minimum inhibitory concentration (MIC) 41 as compared to other broad-spectrum beta-lactam antibiotics (1, 2). Therefore, it is considered a 42 good choice in the empiric management of febrile neutropenia, either as a monotherapy agent or 43 as part of combination regimens (3, 4).
44
Whilst several comparative outcome trials suggest cefepime is clinically as effective as other 45 beta-lactam antibiotics, meta-analyses (5, 6) of data from these trials report an increased risk of 46 mortality associated with cefepime therapy, which was particularly high in febrile neutropenic 47 patients (7). Conversely, a later meta-analysis by the United States' Food and Drug 48 Administration (FDA), which included several additional unpublished trials, concluded that there 49 is no such association (8, 9) . In addition, specific analysis of trials in febrile neutropenic patients 50 did not show any statistically significant increase in mortality (9). The controversy continues as 51 the methodological issues of the FDA's and previous meta-analyses are challenged and debated 52 (7, (10) (11) (12) . However, there is little biological plausibility for the claimed risk of mortality, which 53 was originally suggested to be related to unrecognised toxicity or poor in vivo antibiotic efficacy 
MATERIALS AND METHODS
79
Study setting, patients and drug administration. The study was conducted at The Queen analysis based on the two concentrations measured in the terminal elimination phase.
RESULTS
145
Twelve patients with neutropenic fever and malignancy were enrolled in the study.
146
Characteristics of these study participants are presented in In the context of the growing evidence of altered antibiotic PK and subsequent underexposure in 
177
The median volume of distribution of cefepime estimated in this study is higher than that and the markedly increased BMI/obesity observed in our cohort (Table 1) was attained in 55% of the dosing intervals assessed in this study, when considering the empiric Figure 3 . Box-and-whisker plot of proportions of the dosing interval that the free cefepime concentration remained above the minimum inhibitory concentration of 8 mg/L in twelve febrile neutropenic patients with hematological malignancy receiving 2g IV 8-hourly dosing. The whiskers extend to 1.5 times the interquartile range from Q1 or Q3, or the highest/lowest point within the range.
